A Drosophila model of Alzheimer's disease.
The development of a model of Alzheimer's disease in Drosophila allows us to identify and dissect pathological pathways using the most powerful genetic tools available to biology. By reconstructing essential steps in Alzheimer's pathology, such as amyloid beta peptide and tau overexpression, we can observe clear and rapid phenotypes that are surrogate markers for human disease. The characterization of progressive phenotypes by immunohistochemistry of the brain combined with longevity, climbing, and pseudopupil assays allows the investigator to generate quantitative data. Phenotypes may be modulated by changes in gene expression as part of a genetic screen or by potential therapeutic compounds.
Crowther
Damian C
DC
Department of Medicine, University of Cambridge, CIMR Wellcome Trust, Cambridge, United Kingdom CB2 2XY.
Page
Richard
R
Chandraratna
Dhianjali
D
Lomas
David A
DA
D000544:Alzheimer Disease / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D000818:Animals; D001681:Biological Assay; D001921:Brain / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D004195:Disease Models, Animal; D004330:Drosophila / Q000196:embryology / Q000235:genetics / Q000378:metabolism*; D004625:Embryo, Nonmammalian; D006801:Humans; D007150:Immunohistochemistry; D019076:Transgenes